What happens when new technology legitimizes a market that’s already worth nearly $350 billion?
We are about to find out.
The global cannabis consumer market is worth an estimated $344 billion buoyed by 160 million users, according to New Frontier data. The legal segment of this is growing at a record pace: Jefferies Group projects the legal cannabis market will be worth $130 billion by 2029.
The U.S. and Canada alone are expected to generate $172 billion in retail sales over the next six years, according to New Frontier.
Virtually everyone seems bullish about the future of legal weed.
(Click to enlarge)
However you look at it, the numbers are astounding.
But there’s one big problem with this booming market… The supply chain. It is both vulnerable and lacks transparency, a problem that could be keeping marijuana from growing into a trillion-dollar industry.
And the best thing? There’s no apparent competition yet.
For cannabis right now, the difference between a multi-billion-dollar industry and a potential trillion-dollar industry seems to be quality and provenance.
That requires a global technological solution that can secure every single strain on the planet for consumers.
And the company first out of the gates in this game could likely have a major advantage.
Reason #1: Legalization Drive = Explosive growth for $146B industry
Marijuana is fast losing its reputation as a grungy, pothead gateway drug, rebranding itself as modern, premium and artisanal – all thanks to the global legalization drive.
Just look at the U.S. cannabis legalization map, which only tells a part of this global story:
(Click to enlarge)
You can now light up legally in Canada, the District of Columbia, 30 different states in the U.S., Mexico, Belize, Costa Rica, Jamaica, Colombia, Ecuador, Peru, Argentina, Uruguay, Cambodia and Laos. Many more will soon follow.
According to the UN, a staggering 158.8 million people, or nearly 4 percent of the world’s population, now consume marijuana.
But here’s the alarming part: although the trend toward legalization for both medicinal and recreational purposes has been moving full steam ahead, the black market for marijuana remains massive. Despite the incredible potential of this emerging market, legal cannabis only made up $11.9 billion of the U.S. market in 2018.
And this trend rings true in Canada as well, the world’s biggest legal weed venue.
During the final quarter of 2018, nearly 80 percent of Canadian weed sales were through the black market – a slight improvement from 90 percent the previous quarter.
Part of the reason for this curious trend is the fact that legal weed costs more than its illegitimate brethren, but the bigger reason has to do with supply chain issues (the Canadian government has curtailed retail hours and limited licensing distributions mainly due to health and safety concerns).
Luckily for marijuana investors, all that is about to change…fast.
According to industry estimates, the global legal cannabis industry is expected to experience explosive growth that will hit $146.4 billion by the end of 2025.
The future of the legal weed industry is bullish to the extent that even a famous Wall Street short-seller is calling it “The Big Long”.
However, it simply won’t get there without legitimacy.
The crippling bottlenecks in the marijuana supply chain need to be ironed out ASAP.
Luckily, the turning point for the industry has finally arrived.
TruTrace’s (CSE:TTT; OTC:TTTSF proprietary StrainSecure seed-to-sale tracking technology, the first in the marijuana industry, is a genuine gamechanger that’s set to significantly speed up the industry’s legalization push.
Reason #2: Wide moat company with first-of-a-kind tracking tech
The legal weed industry is facing some formidable challenges.
– A disparate and highly fractured supply chain fueling a massive black market…
– Lack of product quality and consistency…
– A growing trend of piracy and counterfeiting brands…
That’s why state regulators are demanding strict seed-to-sale tracking capabilities that will allow companies to seamlessly monitor legalized marijuana products across the supply chain.
That means monitoring where it was planted, harvested, processed, and ultimately – sold.
Consider this: each year, more than 1,000 tons of illegal marijuana are seized along the U.S.-Mexico border. That’s weed worth millions of dollars going to fund criminal activities.
Just like the jewelry industry is now using IBM’s blockchain technology to trace the origin of diamonds in a bid to filter out blood diamonds, the cannabis industry badly needs tracking tech for provenance and for preventing harmful or illegal products into the marketplace.
TruTrace Technologies has developed StrainSecure, the industry’s first integrated blockchain platform to register and track intellectual property in the cannabis industry.
This advanced blockchain technology establishes a single-source, accurate, validated and permanent account for any cannabis strain – all the way to the market.
Even better: The digital platform also streamlines the administrative process, lowering the costs related to genetic and mandatory quality-control testing for legal cannabis.
Each time a product is tested and verified by the network, a Registration Affidavit is auto-generated and assigned a unique StrainSecure Address traceable through a QR Code.
Producers, patients and consumers can not only verify and test their products but also rate them and share reviews. These details are secured on the StrainSecure blockchain and cannot be altered by any one party.
(Click to enlarge)
Incredibly, they have built this proprietary platform in-house, with a team with 21 years of large-scale enterprise software development for fortune 500 companies such as Microsoft and Mercedes Benz, as well as 8 years of experience in the cannabis and supply chain industry.
They are so confident in their product that they don’t see any other company having anything like it for years to come.
This gives TruTrace a huge first-mover advantage and an incredibly wide moat that it can exploit for years to come…
Another advantage: TruTrace has signed a deal with Strainprint, a leading source of medical cannabis use data with more than 60 million data points from 1.2 million medical cannabis patients with reported outcomes.
Instead of being a chess piece on a crowded board, TruTrace has positioned itself as the board itself.
This is the epicenter of legal marijuana testing. It’s the lucrative starting point for the entire industry’s drive for transparency, standardization and compliance.
Reason #3: High revenue potential
Having a first-mover advantage in the modern tech world is almost always a ticket to breakout revenue and profits…
Not to mention nearly endless growth runways…
For TruTrace, the possibilities for growth are extremely attractive.
They already have the attention of the large medical community in the Canadian market-place and some in the US market-place.
And the company just signed a deal with one of the biggest drug distributors in Canada—with more than 1200 brick-and-mortar stores.
Next to this, the company is working on a deal that it hopes will bring in several of the top producers in the Canadian market-place, and potentially many more from the U.S. and then the rest of the world.
Why? Because it’s the only tech of its kind available, and because the cannabis industry is in desperate need of it.
One of TruTrace’s key markets are marijuana distributors – with more than 100 pot shops in Canada and over 2,000 dispensaries in the United States, it’s safe to say the company’s StrainSecure product will likely find a very ready and healthy market.
The outlook is certainly very compelling…
The cannabis testing market is rapidly taking off and is expected to grow from $1.5 billion currently to $2.4 billion over the next 5 years.
The food safety testing market is much bigger, currently valued at $14 billion and expected to exceed $23 billion by 2025.
TruTrace (CSE:TTT; OTC:TTTSF) has already performed test runs on the StrainSecure platform and has received permission to deploy a blockchain-secured pilot program to help tackle some of the industry’s biggest problems.
The company’s management estimates that the company could hit $7-10 million in annual revenues from a standing start. They think that could grow to $25-$50 million in a few years as the company ramps up its distribution channels.
Mind you, this is a company currently valued at just $25 million.
Reason #4: Considerable M&A Potential
(Click to enlarge)
Source: Marijuana Business Daily
The green rush is well and truly underway.
Currently, corporate tie-ups are all the rage in the marijuana sector.
Some very large transactions have sparked the cannabis sector lately, and much more is expected to come.
Mostly it’s been big pot and big tobacco buying marijuana companies in multi-billion-dollar deals in the hope of getting a piece of the action.
– Constellation Brands’(NYSE:STZ) invested $4 billion investment into Canopy Growth Corporation (NYSE:CGC)
– Altria Group Inc. (NYSE:MO) has agreed to take a $1.8B minority stake in Cronos Group Inc.(NASDAQ:CRON).
– Aurora Cannabis Inc (NYSE:ABC) has agreed to buy smaller rival CanniMed Therapeutics Inc. for C$1.1 billion ($852 million.
One big risk: the marijuana growers and producers is an overcrowded industry and a major shakeout appears imminent. Concerns surrounding overproduction have repeatedly come up with fears that too much weed could crash the market.
In any crowded industry, only the most differentiated companies survive, i.e. those with the smartest and most unique solutions that cannot be easily duplicated. TruTrace (CSE:TTT; OTC:TTTSF) (formerly BlockStrain) has been identified as one of the few companies using technology in a unique way to transform the marijuana industry.
Who could potentially acquire TruTrace?
There’s literally an endless list of companies that could be interested in buying this gem.
It could be any of the 100 or so public companies that operate in the medical and legal marijuana sector.
Or any of the thousands of private producers and distributors…
Or any of the hundreds in the food safety testing industry…
It could even be one of several companies that have already struck deals or Joint Ventures with TruTrace
Let’s now examine what TruTrace could fetch in such a scenario…or when the market finally wakes up to its true potential.
Reason #5: Explosive upside potential stock
You will be hard-pressed to find any industry that has gone through such explosive growth as the marijuana sector has over the past few years.
Tens of thousands of investors have realized incredible returns on marijuana investments…
Even after the latest correction, Cronos Group stock is still up a staggering 6,500 percent over the past three years…
Source: CNN Money
Aurora Cannabis stock has rallied more than 2,000 percent over the past 36 months…
Source: CNN Money
While Aphria Inc. has gained nearly 500 percent over the timeframe…
Source: CNN Money
Despite concerns about frothy valuations, investors have continued to flock to marijuana stocks with the medicine and legal marijuana sector rallying 25 percent in the year-to-date, nearly doubling the return by the market benchmark S&P 500.
Source: New Cannabis Ventures
So, how does TruTrace stock stack up?
The great part is that unlike many marijuana companies, TruTrace has zero debt on its books and technology that could potentially expand well beyond the cannabis industry.
Early-in investors have a chance to make a potential killing off this company, regardless of whether it gets acquired or continues to grow organically.
As Alan Brochstein, Founding Partner of New Cannabis Ventures, has aptly observed: “Companies with unique assets or business models are likely to be more appealing to potential buyers. Different geographies or modes of production are often cited by the buying companies, Consolidation is picking up in the cannabis space, and investors are rewarding the companies that are buying by pushing their stocks up after the deals are announced. This will likely encourage other companies to be me more aggressive in their M&A strategies.’’
TruTrace ticks all the right boxes.
Other companies looking to ride the cannabis wave:
Curaleaf Holdings (NASDAQOTH:CURLF) (TSX: CURA)
Curaleaf is a multi-faceted U.S. cannabis company, operating dispensaries, cultivating product, marketing and more. The company also produces a wide range of cannabis products, including concentrates, edibles, tinctures, capsules, vaporizer cartridges, and dry natural marijuana.
Despite the fact that the company only just went public, it has seen a lot of attention from investors, securing a valuation of over $4.5 billion.
Curaleaf’s third-quarter financials shocked analysts, with Q3 revenue soaring by 289 percent. “Boasting the largest retail dispensary footprint under a single, unified brand, with now 33 locations across 10 states, Curaleaf has established itself as a leader in the burgeoning U.S. cannabis industry,” CEO Joe Lusardi noted.
OrganiGram Holdings (NASDAQOTH: OGRMF) (TSX.V: OGI)
OrganiGram is another Canadian holdings company looking to take the burgeoning cannabis industry by the horns. With numerous subsidiaries from which it produces and distributes recreational and medical marijuana, OrganiGram is well positioned to ride the next Green Wave into profits.
OrganiGram has carved out its place in cannabis royalty by securing deals across Canada, from Saskatchewan to British Columbia. In addition to its in-person sales strategy, OrganiGram also offers another unique method of distribution. Online and over-the-phone options. More than that, however, OrganiGram and its partners knows how to manage the surging Canadian demand that has left other distributors without product for periods of time.
In a recent press release following Canada’s landmark legalization event, the company applauded domestic partners for their efforts in managing exceptional consumer demand. “The company is also pleased to have collaborated with provinces and other jurisdictional partners across the country, supporting the successful launch of this new market,” the release read.
CannTrust Holdings Inc. (OTCMKTS:CNTTF) (TSX: TRST)
Canntrust is a cannabis company focusing on the numerous medical benefits of the plant. They offer a number of cannabis-derived products, from CBD and THC pills to actual plant matter.
In September, the company made history with the first approved shipment of a cannabis product to Denmark. The company shipped cannabis oils overseas in a breakthrough deal with its Danish joint venture partner, STENOCARE.
“Thanks to CannTrust’s consistent quality and standardized products, we are the first in Denmark to have cannabis oil products approved for the market,” noted Thomas S. Schnegelsberg, CEO of STENOCARE.
Emblem Corp. (OTCMKTS:EMMBF) (TSX.V: EMC)
Emblem is a leading licensed marijuana producer in Canada. With a number of cannabis-based products, Emblem works closely with the medical community to ensure both patients and physicians have the information necessary to make decisions regarding treatments involving marijuana.
Recently, Emblem completed testing on a new oral extended release product with partner Canntab Therapeutics. With the successful tests, the companies announced that they will be moving forward into clinical trials.
In addition to its advancements in the medial field, Emblem is also working towards a safer community, partnering with DriveABLE in an effort to curb accidents from impaired drivers. Nick Dean, CEO, Emblem Corp. explained, “Impairment – whether from alcohol, cannabis, fatigue, underlying medical conditions, or narcotics – is a serious issue that affects safety on roads and in the workplace.”
THC Biomed International (OTCMKTS:THCBF) (TSX:THC)
THC Biomed operates as a licensed producer under Canada’s Marihuana for Medical Purposes Regulations. It is also engaged in the research & development of the products and services to medical marijuana.
THC Biomed’s recently announced a new THC-based beverage, aiming to appeal to a broader range of consumers. John Miller CEO explained, “THC has conducted extensive research on cannabis edibles and beverages and I have found our product to be exclusive in its category.”
Though THC Biomed may be smaller than some of its more well-known competitors, it is just as ambitious. And it’s beginning to pay off. Earlier this month, the company made its first shipment of cannabis products to its Saskatchewan partner, and is rapidly expanding its holdings, with two new strata lot purchases, adding to its growing array of assets.
By. Meredith Taylor
IMPORTANT NOTICE AND DISCLAIMER
PAID ADVERTISEMENT. This communication should be viewed as a paid advertisement. Leacap Ltd and Safehaven and their owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher was not specifically paid for this communication. However, a related company was previously compensated by Tru Trace Technologies In May 2018, to produce and disseminate other similar articles and certain banner ads. This compensation should be viewed as a major conflict with our ability to be unbiased.
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP. The owner of Safehaven owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies’ stock perform well. The owner of Safehaven has no present intention to sell any of the issuer’s securities in the near future but does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The owner of Safehaven will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies, the success of the companies’ technology, the size and growth of the market for the companies’ products and services, the companies’ ability to fund their capital requirements in the near term and long term, pricing pressures, etc.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY. Safehaven is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.